Company profile: Athira Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage biotechnology and pharmaceutical drug development focused on neurodegenerative diseases. Develops small-molecule therapies including fosgonimeton, which enhances hepatocyte growth factor/MET activity for conditions like Alzheimer’s and Parkinson’s, and ATH-1105, a positive modulator of the neurotrophic HGF system for ALS. Conducts clinical trials to assess safety and efficacy.
Products and services
- ATH-1105: Small-molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system engineered to treat ALS by reducing inflammation and protein pathology while protecting against neurodegeneration
- Clinical Trials: Clinical-stage studies that evaluate the safety and efficacy of Athira’s investigational therapies—including fosgonimeton—across neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS
- Fosgonimeton: Small-molecule that enhances hepatocyte growth factor (HGF) and its receptor MET activity, targeting neurodegenerative diseases including Alzheimer’s and Parkinson’s disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Athira Pharma
Addrenex Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical drug development focused on creating drugs that regulate the adrenergic system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Addrenex Pharmaceuticals company profile →
Vico Therapeutics
HQ: The Netherlands
Website
- Description: Provider of RNA-modulating therapies for rare neurological/CNS disorders, focused on SCA, HD and RTT. Offers VO659, an antisense oligonucleotide targeting CAG repeat expansions in polyglutamine diseases (Spinocerebellar Ataxia types 1/3 and Huntington’s) to reduce mutant protein levels and improve motor function, and VICOMER, a platform designing RNA therapeutics via translation, splicing, editing, degradation and activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vico Therapeutics company profile →
Aspen Neuroscience
HQ: United States
Website
- Description: Provider of personalized, autologous iPSC-derived neuron replacement therapies for Parkinson’s disease. Pipeline includes ANPD001, a personalized cell therapy for sporadic Parkinson’s disease in IND-enabling studies, and ANPD002, a gene-corrected autologous neuron therapy targeting genetic variants, focusing on the GBA gene.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspen Neuroscience company profile →
Alto Neuroscience
HQ: United States
Website
- Description: Provider of an AI-driven biomarker platform that integrates patients’ brain activity and behavior to identify likely responders and enable precision medicines, plus a clinical-stage pipeline for neuropsychiatric conditions, including ALTO-100 (BDNF) for MDD/PTSD, ALTO-300 for MDD, ALTO-202 (NMDA NR2B) for MDD/PTSD, and ALTO-101 (PDE4) for schizophrenia and other neuropsychiatric conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alto Neuroscience company profile →
Probiodrug
HQ: Germany
Website
- Description: Provider of drug discovery and development focused on molecules for the treatment of neuronal and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Probiodrug company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Athira Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Athira Pharma
2.2 - Growth funds investing in similar companies to Athira Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Athira Pharma
4.2 - Public trading comparable groups for Athira Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →